Gilead | michrxconsulting.com

July 16, 20180Comments

State Prisons Fail To Offer Cure To 144,000 Inmates With Deadly Hepatitis

Siraphob Thanthong-Knight State prisons across the U.S. are failing to treat at least 144,000 inmates who have hepatitis C, a curable but potentially fatal liver disease, according to a recent survey

July 3, 20180Comments

Out-Of-Pocket Costs Put HIV Prevention Drug Out Of Reach For Many At Risk

Shefali Luthra, Kaiser Health News and Anna Gorman, Kaiser Health News Public health officials are expanding efforts to get the HIV prevention pill into the hands of those at risk, in

October 4, 20170Comments

Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment

By Michelle Andrews October 3, 2017 Valerie Green is still waiting to be cured. The Delaware resident was diagnosed with hepatitis C more than two years ago, but she doesn’t qualify yet

July 25, 20170Comments

IAS 2017: HIV and the Liver: Co-Infection and Complications

Some more information from IAS 2017 in Paris, France. This video is of the oral abstract presentation on HIV and the Liver: Co-Infection and Complications which consists of 5 abstract presentations

July 13, 20160Comments

Medicaid, Private Insurers Begin To Lift Curbs On Pricey Hepatitis C Drugs

By Judith Graham July 5, 2016 Kaiser Health News After legal battles and lobbying efforts, tens of thousands of people with hepatitis C are gaining earlier access to expensive drugs that can

November 22, 20150Comments

Medicare Spending on Hepatitis C Drugs To Surpass $9B This Year

California Healthline, Monday, November 16, 2015 Medicare spending on breakthrough hepatitis C treatments will increase by nearly twofold this year, surpassing $9 billion, according to data from Medicare's Office of the

March 3, 20150Comments

Drug Transparency Bill May Be First in Nation

by George Lauer, California Healthline Features Editor, California Healthline, Monday, March 2, 2015 A bill in the California Legislature that would require pharmaceutical manufacturers to explain the prices for their expensive

January 30, 20150Comments

PREZCOBIX Approved By FDA

Today the FDA approved Janssen Therapeutics combination HIV antiretroviral, PREZCOBIX which is a combination of darunavir 800mg and cobicistat 150mg. PREZCOBIX is indicated for the treatment of HIV-1 in combination with

January 29, 20150Comments

EVOTAZ Approved By FDA

Today the FDA approved Bristol-Myers Squibb Company’s new HIV antiretroviral combination EVOTAZ. Evotaz is a combination of atazanavir and Cobicistat and is approved for the treatment of HIV-1 infection in

June 24, 20140Comments

Health Insurance Companies Press Pharma on Drug Prices

Health insurance companies are now holding the “feet” of the drug companies to the fire, by refusing to cover their drugs unless they slow the rise in drug prices especially

by Michelle